Citations

Clear

959 citation(s) found for "Service, F J".

Autonomic Cardiovascular Control in Health and Disease
Somers, Virend K., Karim, Shahid, Chahal, C. Anwar A. , Khanji, Mohammed Y , Petersen, Steffen E.

Mayo Clinic

Comprehensive Physiology | April 3, 2025 | Volume: 13 | Issue: 2 | Pages: 4493-4511

10.1002/j.2040-4603.2023.tb00257.x Get It

Abstract Autonomic neural control of the cardiovascular system is formed of complex and dynamic processes able to adjust rapidly to mitigate perturbations in hemodynamics and maintain homeostasis. Alterations in autonomic control feature in the development or progression of a multitude of diseases with wide‐ranging physiological implications given the neural system's responsibility for controlling inotropy, chronotropy, lusitropy, and dromotropy. Imbalances in sympathetic and parasympathetic neural control are also implicated in the development of arrhythmia in several cardiovascular conditions sparking interest in autonomic modulation as a form of treatment. A number of measures of autonomic function have shown prognostic significance in health and in pathological states and have undergone varying degrees of refinement, yet adoption into clinical practice remains extremely limited. The focus of this contemporary narrative review is to summarize the anatomy, physiology, and pathophysiology of the cardiovascular autonomic nervous system and describe the merits and shortfalls of testing modalities available. © 2023 American Physiological Society. Compr Physiol 13:4493‐4511, 2023.
The diagnostic role of pharmacological provocation testing in cardiac electrophysiology: a clinical consensus statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC, t
Behr, Elijah R. , Winkel, Bo Gregers , Ensam, Bode , Alfie, Alberto , Arbelo, Elena , Berry, Colin , Conte, Giulio , Crotti, Lia , Corcia, M. Cecilia Gonzalez , Kaski, Juan Carlos , Schulze‐Bahr, Eric , Wilde, Arthur A.M. , Tfelt‐Hansen, Jacob , Wolpert, Christian, Cuesta, Alejandro, Damman, Peter, Dobrev, Dobromir, Drago, Fabrizio, Haugaa, Kristina, Krahn, Andrew, Krause, Ulrich, Lambiase, Pier D, Napolitano, Carlo, Odening, Katja E, Shimizu, Wataru, Veltmann, Christian, Lambiase, Pier D. , Odening, Katja E. , Cerrone, Marina , Conte, Giulio , Crotti, Lia , Kaski, Juan Carlos , Nademanee, Koonlawee , Postema, Pieter G , Priori, Silvia , Probst, Vincent , Sarquella-Brugada, Georgia , Schulze-Bahr, Eric , Tadros, Rafik , Wilde, Arthur A M , Tfelt-Hansen, Jacob , Behr, Elijah Raphael , Lambiase, Pier D , Odening, Katja E , Arbelo, Elena , Berry, Colin , Cerrone, Marina , Nademanee, Koonlawee , Postema, Pieter G. , Priori, Silvia G. , Tadros, Rafik , Wolpert, Christian, Cuesta, Alejandro, Damman, Peter, Dobrev, Dobromir, Drago, Fabrizio, Haugaa, Kristina, Krahn, Andrew, Krause, Ulrich, Napolitano, Carlo, Shimizu, Wataru, Veltmann, Christian

Mayo Clinic

Europace | April 1, 2025 | Volume: 27 | Issue: 4 | Pages: No page available

10.1093/europace/euaf067 | PMID 40165484 Get It

Abstract The pharmacological provocation test is a pivotal tool in cardiac electrophysiology for the diagnosis of potential causes of sudden cardiac death, sudden cardiac arrest (SCA), arrhythmias, symptoms, or ECG abnormalities. The 2022 European Society of Cardiology Guidelines for the Treatment of Ventricular Arrhythmias and Prevention of Sudden Cardiac Death offered guidance on provocation testing but did not describe the indications and requirements in depth. This clinical consensus statement, led by the European Heart Rhythm Association and approved by major international stakeholders, aims to advise the general cardiologist and the arrhythmia expert who to test and when, where, and how to do it. The statement focuses on current practice for the diagnosis of subclinical arrhythmia syndromes and the causes of SCA, building upon the recommendations of the Guidelines. We address the sodium channel blocker provocation test for patients suspected of Brugada syndrome as well as the use of epinephrine, isoproterenol, adenosine, ergonovine, and acetylcholine.
Factors Associated With Stroke Recurrence After Initial Diagnosis of Cervical Artery Dissection
Mandel, Daniel , Shu, Liqi , Chang, Christopher , JACK, N , Henninger, Nils , Muppa, Jayachandra , Affan, Muhammad , Lodhi, Omair ul haq , Heldner, Mirjam R. , Omran, Setareh Salehi , Crandall, Ross , Lester, Evan, Araúz, Antonio , Boulanger, Marion , Sousa, João André , Barata, Vasco , Castro‐Chaves, Paulo , Brito, Maria Teresa , Khan, Muhib , Mallick, Dania, Rothstein, Aaron , Khazaal, Ossama , Traenka, Christopher , Sousa, Diana Aguiar de , Soares, Mafalda , Rosa, Sara , Zhou, Lily , Gandhi, Preet , Field, Thalia S. , Mancini, Steven, Pan, Kelly , Dantu, Vishnu , Baumgartner, Karl , Nolte, Christian H. , Choi, Richard , Macdonald, J , Ghannam, Malik , Almajali, Mohammad , Sanchez, Sebastian , Zine-Eddine, Fayçal, Poppe, Alexandre Y. , Fonseca, Ana Catarina , Baptista, Maria Fortuna , Cruz, Diana , Marco, Giovanna De , Griffin, Kim J. , Kuohn, Lindsey , Frontera, Jennifer , Amar, Jordan , Grisendi, Ilaria , Nzwalo, Hipólito , Liebeskind, David S. , Molaie, Amir , Cavalier, Annie, Kam, Wayneho , Grory, Brian Mac , Kasab, Sami Al , Eltatawy, Ali , Chervak, Lina , Rivas, Roberto Chulluncuy, Bakradze, Ekaterina , Tran, Thanh Lam , Ortiz-Garcia, Jorge , Muddasani, Varsha , Vishnu, Venugopalan Y. , Yaddanapudi, Sridhara , Adams, L, Browngoehl, Abigail, Dunston, Randy, Lynch, Zachary, Penckofer, Mary , Mayer, Silvia, Zubair, Adeel , Cheng, Yee Kuang, Ferreira, Vítor Mendes , Asad, Syed Daniyal , Sarwat, Zoha, Balabhadra, Anvesh , Patel, Shivam , Secchi, Thaís , Mantovani, Gabriel Paulo , Krishnaiah, Balaji , Lingam, Sivani, Khasiyev, Farid , Linares, Guillermo , Mannino, Marina , Terruso, Valeria, Vassilopoulou, Sofia , Tentolouris-Piperas, Vasileios , Wall, Victor Carrasco , Indraswari, Fransisca , Jamal, Sleiman El , Liu, Shilin, Alvi, Muhammad , Sarvath, Mohammed, Kass‐Hout, Tareq , Shi, Feina , Zhang, Jinhua , Said, Jamil , Mongare, Newnex, Sen, Shayak, Ghani, Mohammad R , Elnazeir, Marwa , Xiao, Han , Khan, Farhan , Mohammadzadeh, Nahid , Furie, Karen L. , Mandel, Daniel M , Jack, Naomi , Leon Guerrero, Christopher R , Henninger, Nils , Muppa, Jayachandra , Heldner, Mirjam R , Antonenko, Kateryna , Seiffge, David , Arnold, Marcel , Salehi Omran, Setareh , Crandall, Ross , Lopez Mena, Diego , Arauz, Antonio , Boulanger, Marion , Touzé, Emmanuel , Sousa, Joao Andre , Sargento-Freitas, Joao , Barata, Vasco , Castro-Chaves, Paulo , Brito, Maria Teresa , Khan, Muhib , Rothstein, Aaron , Khazaal, Ossama , Kaufman, Josefin E , Engelter, Stefan T , Traenka, Christopher , Aguiar de Sousa, Diana , Soares, Mafalda , Rosa, Sara , Zhou, Lily W , Gandhi, Preet , Field, Thalia S , Metanis, Issa , Leker, Ronen R , Dantu, Vishnu , Baumgartner, Karl , Burton, Tina , von Rennenberg, Regina , Nolte, Christian H , Choi, Richard , MacDonald, Jason , Bavarsad Shahripour, Reza , Guo, Xiaofan , Ghannam, Malik , Almajali, Mohammad , Samaniego, Edgar A , Sanchez, Sebastian , Rioux, Bastien , Poppe, Alexandre , Fonseca, Ana Catarina , Fortuna Baptista, Maria , Cruz, Diana , Romoli, Michele , Longoni, Marco , Keser, Zafer , Kuohn, Lindsey , Frontera, Jennifer , Giles, James , Zedde, Marialuisa , Pascarella, Rosario , Grisendi, Ilaria , Nzwalo, Hipolito , Liebeskind, David S. , Molaie, Amir , Kam, Wayneho , Mac Grory, Brian , Al Kasab, Sami , Anadani, Mohammad , Kicielinski, Kimberly , Eltatawy, Ali , Chervak, Lina , Aziz, Yasmin , Bakradze, Ekaterina , Rodrigo Gisbert, Marc , Requena, Manuel , Saleh Velez, Faddi , Garcia, Jorge Ortiz , Muddasani, Varsha , de Havenon, Adam H , Vishnu, Venugopalan Y , Adams, Latasha , Ranasinghe, Tamra , Penckofer, Mary , Siegler, James E , Mayer, Silvia , Willey, Joshua , Zubair, Adeel , Cheng, Yee Kuang , Sharma, Richa , Marto, João Pedro , Mendes Ferreira, Vítor , Klein, Piers , Nguyen, Thanh N , Asad, Syed Daniyal , Balabhadra, Anvesh , Martins, Sheila , Mantovani, Gabriel , Kim, Young Dae , Krishnaiah, Balaji , Elangovan, Cheran , Qureshi, Abid Y , Fridman, Sebastian , Alvarado-Bolanos, Alonso , Khasiyev, Farid , Linares, Guillermo , Mannino, Marina , Terruso, Valeria , Vassilopoulou, Sofia , Tentolouris-Piperas, Vasileios , Martinez Marino, Manuel , Carrasco Wall, Victor , Indraswari, Fransisca , El Jamal, Sleiman , Liu, Shilin , Sarvath, Mohammed , Morsi, Rami Z , Kass-Hout, Tareq , Shi, Feina , Zhang, Jinhua , Sokhi, Dilraj , Simpkins, Alexis N , Ghani, Mohammad , Elnazeir, Marwa , Xiao, Han , Khan, Farhan , Stretz, Christoph , Goldstein, Eric D , Furie, Karen L , Yaghi, Shadi , Seiffge, David , Nehme, Ahmad , Sargento‐Freitas, João , Kaufmann, Josefin E. , Engelter, Stefan T. , Metanis, Issa , Shahripour, Reza Bavarsad , Guo, Xiaofan , Keser, Zafer , Giles, James , Zedde, Marialuisa , Pascarella, Rosario , Aziz, Yasmin , Rodrigo‐Gisbert, Marc , Requena, Manuel , Velez, Faddi G. Saleh , Havenon, Adam de , Ranasinghe, Tamra , Siegler, James E. , Sharma, Richa , Marto, João Pedro , Klein, Piers , Nguyen, Thanh N. , Kim, Young Dae , Elangovan, Cheran , Alvarado‐Bolaños, Alonso , Martínez-Marino, Manuel , Ali, Farman, Morsi, Rami Z. , Simpkins, Alexis N. , Gomez, Roberto, Sen, Shayak, Kala, Narendra , Stretz, Christoph , Goldstein, Eric , Yaghi, Shadi

Mayo Clinic

Stroke | March 27, 2025 | Volume: 56 | Issue: 6 | Pages: 1413-1421

10.1161/strokeaha.124.048215 | PMID 40143807 Get It

BACKGROUND: Patients presenting with cervical artery dissection (CAD) are at risk for subsequent ischemic events. We aimed to identify characteristics that are associated with increased risk of ischemic stroke after initial presentation of CAD and to evaluate the differential impact of anticoagulant versus antiplatelet therapy in these high-risk individuals. METHODS: This was a preplanned secondary analysis of the STOP-CAD study (Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection), a multicenter international retrospective observational study (63 sites from 16 countries in North America, South America, Europe, Asia, and Africa) that included patients with CAD predominantly between January 2015 and June 2022. The primary outcome was subsequent ischemic stroke by day 180 after diagnosis. Clinical and imaging variables were compared between those with versus without subsequent ischemic stroke. Significant factors associated with subsequent stroke risk were identified using stepwise Cox regression. Associations between subsequent ischemic stroke risk and antithrombotic therapy type (anticoagulation versus antiplatelets) among patients with identified risk factors were explored using adjusted Cox regression. RESULTS: In all, 4023 patients (mean age was 47.4 years; 44.5% were women) were included. By day 180, subsequent ischemic stroke occurred in 5.3% of the cohort. In adjusted Cox regression, factors associated with increased risk of subsequent ischemic stroke were prior history of ischemic stroke (adjusted hazard ratio [aHR], 7.31 [95% CI, 1.61–33.13]; P =0.010), presentation within 7 days from first symptoms (aHR, 3.04 [95% CI, 1.04–8.91]; P =0.043), infarct on baseline imaging (aHR, 9.85 [95% CI, 3.65–26.58]; P <0.001), and occlusive dissection (aHR, 2.34 [95% CI, 1.03–5.34]; P =0.043). Only patients with occlusive dissection demonstrated a reduced risk of subsequent ischemic stroke when treated with anticoagulation versus antiplatelets (aHR, 0.36 [95% CI, 0.16–0.80]; P =0.01). CONCLUSIONS: In this post hoc analysis of the STOP-CAD study, several factors associated with subsequent ischemic stroke were identified among patients with CAD. Furthermore, we identified a potential benefit of anticoagulation in patients with CAD with occlusive dissection. These findings require validation by meta-analyses of prior studies to formulate optimal treatment strategies for specific high-risk CAD subgroups.
Hypertension and Atrial Fibrillation: A Frontier Review From the AF-SCREEN International Collaboration
Schnabel, Renate B. , Schutte, Aletta E. , Buckley, Claire , Cameron, Alan C. , Damasceno, Albertino , Diederichsen, Søren Zöga , Doehner, Wolfram , Joung, Boyoung , Hankey, Graeme J. , Lobban, Trudie , Mairesse, Georges H. , Svendsen, Jesper Hastrup , Tieleman, Robert G , Wang, Ji‐Guang , Niiranen, Teemu J , Schnabel, Renate B , Schutte, Aletta E , Boriani, Giuseppe , Buckley, Claire , Cameron, Alan C , Damasceno, Albertino , Diederichsen, Søren Z , Doehner, Wolfram , Guo, Yutao , Hobbs, F D Richard , Joung, Boyoung , Hankey, Graeme J , Lip, Gregory Y H , Lobban, Trudie , Løchen, Maja-Lisa , Mairesse, Georges , Mbakwem, Amam , Noseworthy, Peter A , Steinhubl, Steven , Stergiou, George , Svendsen, Jesper Hastrup , Tieleman, Robert G , Wang, Ji-Guang , Poulter, Neil R , Healey, Jeffrey S , Freedman, Ben , Biton, Yitschak , Boriani, Giuseppe , Hobbs, Richard , Mbakwem, Amam , Noseworthy, Peter A. , Ntaios, George , Stergiou, George S. , Healey, Jeff S. , Freedman, Ben

Mayo Clinic

Circulation | March 24, 2025 | Volume: 151 | Issue: 12 | Pages: 863-877

10.1161/circulationaha.124.071047 | PMID 40127157 Get It

Hypertension is the leading modifiable risk factor for atrial fibrillation (AF) and is estimated to be present in >70% of AF patients. This Frontiers Review was prepared by 29 expert members of the AF-SCREEN International Collaboration to summarize existing evidence and knowledge gaps on links between hypertension, AF, and their cardiovascular sequelae; simultaneous screening for hypertension and AF; and the prevention of AF through antihypertensive therapy. Hypertension and AF are inextricably connected. Both are easily diagnosed, often silent, and frequently treated inadequately. Together, they additively increase the risk of ischemic stroke, heart failure, and many types of dementia, resulting in greater all-cause mortality, considerable disease burden, and increased health care expenditures. Automated upper arm cuff blood pressure devices with implemented technology can be used to simultaneously detect both hypertension and AF. However, positive screening for AF with an oscillometric blood pressure monitor still requires ECG confirmation. The current evidence suggests that high-risk individuals aged ≥65 years or with treatment-resistant hypertension could benefit from AF screening. Since antihypertensive therapy effectively lowers AF risk, particularly in individuals with left ventricular dysfunction, hypertension should be the key target for AF prediction and prevention rather than merely a comorbidity of AF. Nevertheless, several important gaps in knowledge need to be filled over the next years, including the ideal method and selection of patients for simultaneous screening of hypertension and AF and the optimal antihypertensive drug class and blood pressure targets for AF prevention.
Utilizing Patient Input in Rectal Cancer Trial Design
Alvarez, Janet , Zambare, Wini , George, Manju, Garcia, Reese , Gallagher, Phuong , Kitchens, Caleah , Bercz, Aron , Kim, Min Jung , Romesser, Paul B. , Cercek, Andrea , Sanoff, Hanna K. , Hong, Theodore S. , Baghdadi, Tareq Al, Shergill, Ardaman , Meyerhardt, Jeffrey A. , Horvat, Natally , Hall, William A., Smith, J. Joshua , Sanoff, Hanna , George, Thomas J , Hong, Theodore S , Yothers, Greg , Philip, Philip , Alese, Olatunji B , Shergill, Ardaman , O'Reilly, Eileen M , Meyerhardt, Jeffrey A , Horvat, Natally , Dasari, Arvind N , Shi, Qian , Schrag, Deborah , Smith, J Joshua , Romesser, Paul B , Baghdadi, Tareq Al , Kitchens, Caleah , García‐Aguilar, Julio , George, Thomas J. , Yothers, Greg , Philip, Philip A. , Alese, Olatunji B. , O’Reilly, Eileen M. , Dasari, Arvind , Shi, Qian

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 20, 2025 | Volume: 117 | Issue: 7 | Pages: 1421-1428

10.1093/jnci/djaf074 | PMID 40108482 Get It

Abstract Background The treatment of locally advanced rectal cancer now includes “watch-and-wait” (WW) management for patients who exhibit a clinical complete response (cCR) to total neoadjuvant therapy (TNT). We assessed patients’ knowledge and preferences regarding WW with the goal of incorporating patient input into clinical trial design. Methods Rectal cancer patients in advocacy groups (COLONTOWN/Rectalburgh and Fight CRC) were surveyed regarding perceptions about treatment strategies, tolerable risks of treatment failure, and preferences on clinical trial design. Surveys were initially distributed in 2019, with the shift toward WW prompting re-survey of select questions in 2023. Results All respondents preferred enrollment in trials that incorporated patient input. Most respondents (76%) preferred treatment that incorporated chemotherapy escalation over radiation escalation. Furthermore, when presented with a hypothetical patient who developed a cCR after chemoradiation (without the option for WW), 58% of patients chose surgical treatment (with 100% risk of permanent ostomy and 80% chance of cure) over omission of surgery (with &lt;80% chance of cure). In contrast, when the hypothetical patient developed a cCR after TNT (with an option for WW), 82% of patients opted for selective WW over surgery. Conclusions This work successfully integrated patient advocacy groups as a resource for obtaining patient input. Surveys revealed patients had a strong preference for chemotherapy escalation, for selective WW when offered, and for incorporation of input into future clinical trial design. These findings describe how well-informed patients approach complex medical decision-making and serve as a starting point for future studies seeking to incorporate patient voices.
Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT
Hernández‐Boluda, Juan Carlos , Raj, Kavita , Kenyon, Michelle , Robin, Marie , Sockel, Katja , Sánchez‐Ortega, Isabel , Arcaini, Luca , Battipaglia, Giorgia , Ciceri, Fabio , Drozd‐Sokołowska, Joanna , Funke, Vaneuza Araújo Moreira , Gangat, Naseema , Harrison, Claire , Khoury, Joseph D. , Padron, Eric , Patnaik, Mrinal M. , Pemmaraju, Naveen , Radia, Deepti , Reiter, Andreas , Tefferi, Ayalew , Vannucchi, Alessandro M., Polverelli, Nicola , Hernández-Boluda, Juan Carlos , Gurnari, Carmelo , Raj, Kavita , Czerw, Tomasz , Kenyon, Michelle , Robin, Marie , Sánchez-Ortega, Isabel , Arber, Daniel A , Battipaglia, Giorgia , Chalandon, Yves , Cross, Nicholas C P , Drozd-Sokolowska, Joanna , Funke, Vaneuza , Gangat, Naseema , Hobbs, Gabriela S , Jain, Tania , Khoury, Joseph , Kiladjian, Jean-Jacques , Kröger, Nicolaus , Malcovati, Luca , Martino, Massimo , Mesa, Ruben , Palandri, Francesca , Patnaik, Mrinal , Pemmaraju, Naveen , Scheid, Christof , Wiseman, Daniel H , Yakoub-Agha, Ibrahim , Arcaini, Luca , Polverelli, Nicola , Onida, Francesco , Gurnari, Carmelo , Ruggeri, Annalisa , Arber, Daniel A. , Duarte, Fernando Barroso , Battipaglia, Giorgia , Chalandon, Yves , Cross, Nicholas C.P. , Gagelmann, Nico , Gotlib, Jason , Guglielmelli, Paola , Hobbs, Gabriela , Jain, Tania , Kiladjian, Jean‐Jacques , Kröger, Nicolaus , Malcovati, Luca , Martino, Massimo , Mesa, Ruben A. , Orazi, Attilio , Palandri, Francesca , Passamonti, Francesco , Russo, Domenico , Scheid, Christof , Wiseman, Daniel H. , Yakoub‐Agha, Ibrahim , McLornan, Donal P.

Mayo Clinic

Blood | March 19, 2025 | Volume: 145 | Issue: 22 | Pages: 2561-2573

10.1182/blood.2024028000 | PMID 40106773 Get It

Abstract “Nonclassical” myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) represent a heterogeneous group of malignancies characterized by a wide range of clinical manifestations. Unlike classical MPNs, there is no standardized management approach for these conditions, particularly concerning the indications for and management of allogeneic hematopoietic cell transplantation. To address this gap, the European Society for Blood and Marrow Transplantation (EBMT) Practice Harmonization and Guidelines (PH&G) Committee and the Chronic Malignancies Working Party (CMWP) have collaborated to develop shared guidelines aimed at optimizing the selection and management of patients with these rare forms of neoplasms. A comprehensive review of the literature from the publication of the revised fourth edition of the (2016) World Health Organization classification onward was conducted. A multidisciplinary group of experts in the field convened to produce this document, which was developed through multiple rounds of draft circulation. Key recommendations include the early identification of potential transplant candidates, particularly in cases of chronic neutrophilic leukemia, chronic eosinophilic leukemia (CEL)/CEL, not otherwise specified (CEL-NOS), myeloid/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusions with FGFR1, JAK2, ABL1, and FLT3 rearrangements, MDS/MPN with neutrophilia/atypical chronic myeloid leukemia, and MDS/MPN, NOS. For patients with MPN, NOS/MPN unclassifiable, standard recommendations for myelofibrosis should be applied. Similarly, in MDS/MPN with thrombocytosis, transplantation is recommended on the basis of established MDS guidelines. Given the current lack of robust evidence, this document will serve as a valuable resource to guide future research activities, providing a framework for addressing critical unanswered questions and advancing the field.
Copy Number Variation and Haplotype Analysis of 17q21.31 Reveals Increased Risk Associated with Progressive Supranuclear Palsy and Gene Expression Changes in Neuronal Cells
Wang, Hui , Chang, Timothy S. , Dombroski, Beth A. , Cheng, Po‐Liang , Si, Yaqin , Tucci, Albert , Patil, Vishakha, Valiente‐Banuet, Leopoldo , Li, Chong , Farrell, Kurt , Molina‐Porcel, Laura , Rajput, Alex , Gearing, Marla , Newell, Kathy L. , Rábano‐Gutierrez, Alberto, Oertel, Wolfgang H. , Respondek, Gesine , Stamelou, María , Arzberger, Thomas , Roeber, Sigrun, Müller, Ulrich , Pástor, Pau , Ber, Isabelle Le, Beach, Thomas G. , Litvan, Irene , Rademakers, Rosa , Ross, Owen A. , Boxer, Adam L. , Seeley, Willian W., Lee, Edward B. , Silva, Rohan de , Crary, John F. , Goate, Alison , Friedman, Jeffrey S., Compta, Yaroslau , Coppola, Giovanni , Wang, Li‐San , Group, PSP Genetics Study, Tzeng, Jung‐Ying , Geschwind, Daniel H. , Schellenberg, Gerard D. , Si, Ya-Qin , Mclean, Catriona , Molina-Porcel, Laura , Rajput, Alex , Deyn, Peter Paul De , Le Bastard, Nathalie , Gearing, Marla , Donker Kaat, Laura , Van Swieten, John C , Ghetti, Bernardino F , Troakes, Claire , de Yébenes, Justo G , Meller, Tina , Oertel, Wolfgang H , Respondek, Gesine , Hopfner, Franziska , Pastor, Pau , Brice, Alexis , Dürr, Alexandra , Beach, Thomas G , Serrano, Geidy E , Hazrati, Lili‐Naz , Litvan, Irene , Ross, Owen A , Galasko, Douglas , Boxer, Adam , Miller, Bruce L , Deerlin, Vivianna M. Van , Lee, Edward B , White, Charles L , Morris, Huw R , Crary, John F , Goate, Alison M , Leung, Yuk Yee , Wang, Li-San , Dickson, Dennis W , Höglinger, Günter U , Tzeng, Jung-Ying , Schellenberg, Gerard D , Lee, Wan-Ping , Dombroski, Beth , Farrell, Kurt , McLean, Catriona , Kaat, Laura Donker , Swieten, John C. van , Dopper, Elise G.P. , Ghetti, Bernardino , Troakes, Claire , Müller, Ulrich, Hopfner, Franziska , Brice, Alexis , Ber, Isabelle Le , Serrano, Geidy E. , Galasko, Douglas , Miller, Bruce L. , White, Charles L. , Morris, Huw R. , Naj, Adam Christian , Group, PSP Genetics Study, Dalgard, Clifton L. , Dickson, Dennis W. , Höglinger, Günter U.

Mayo Clinic

Movement Disorders | March 12, 2025 | Volume: 40 | Issue: 5 | Pages: 950-961

10.1002/mds.30150 | PMID 40055946 Get It

AbstractBackgroundThe 17q21.31 region with various structural forms characterized by the H1/H2 haplotypes and three large copy number variations (CNVs) represents the strongest risk locus in progressive supranuclear palsy (PSP).ObjectiveTo investigate the association between CNVs and structural forms on 17q.21.31 with the risk of PSP.MethodsUtilizing whole genome sequencing data from 1684 PSP cases and 2392 controls, the three large CNVs (α, β, and γ) and structural forms within 17q21.31 were identified and analyzed for their association with PSP.ResultsWe found that the copy number of γ was associated with increased PSP risk (odds ratio [OR] = 1.10, P = 0.0018). From H1β1γ1 (OR = 1.21) and H1β2γ1 (OR = 1.24) to H1β1γ4 (OR = 1.57), structural forms of H1 with additional copies of γ displayed a higher risk for PSP. The frequency of the risk sub‐haplotype H1c rises from 1% in individuals with two γ copies to 88% in those with eight copies. Additionally, γ duplication up‐regulates expression of ARL17B, LRRC37A/LRRC37A2, and NSFP1, while down‐regulating KANSL1. Single‐nucleus RNA‐seq of the dorsolateral prefrontal cortex analysis reveals γ duplication primarily up‐regulates LRRC37A/LRRC37A2 in neuronal cells.ConclusionsThe copy number of γ is associated with the risk of PSP after adjusting for H1/H2, indicating that the complex structure at 17q21.31 is an important consideration when evaluating the genetic risk of PSP. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Why do people still make anti‐D over 50 years after the introduction of Rho(D) immune globulin? A Biomedical Excellence for Safer Transfusion (BEST) Collaborative study
DelBaugh, Regina M. , Murphy, Michael , Staves, Julie , Fachini, Roberta , Hands, Katie , Bub, Carolina Bonet , Cohn, Claudia S. , Cox, Cody A., Ziman, Alyssa , Fermon, Erica J., Peters, Jessica, Collaborative, BEST foRmation of Anti‐D After Rhogam (RADAR) Study Investigators and the Biomedical Excellence for Safer Transfusion (BEST), Callum, Jeannie , Murphy, Michael , Wendel, Silvano , Bonet-Bub, Carolina , Cohn, Claudia S , Jacquot, Cyril , Hasan, Rida A , Lu, Wen , Juskewitch, Justin E , Raval, Jay S , Fung, Mark K , Ziman, Alyssa , Dunbar, Nancy M , Kutner, José Mauro , Cox, Cody A., Jacquot, Cyril , Hasan, Rida A. , Lu, Wen , Juskewitch, Justin E. , Raval, Jay S. , Rollins‐Raval, Marian A. , Gorlin, Jed B. , Dunbar, Nancy M. , Collaborative, BEST foRmation of Anti‐D After Rhogam (RADAR) Study Investigators and the Biomedical Excellence for Safer Transfusion (BEST)

Mayo Clinic

Transfusion | March 10, 2025 | Volume: 65 | Issue: 5 | Pages: 957-967

10.1111/trf.18202 | PMID 40059673 Get It

Abstract Background Rho(D) immune globulin (RhIg) is used to reduce RhD alloimmunization in pregnancy. This study describes potential causes for RhD alloimmunization after the development and implementation of RhIg. Study Design and Methods This retrospective descriptive study investigated RhD‐negative patients born in 1965–2005 with anti‐D newly identified during 2018–2022. Transfusion, pregnancy, intravenous drug abuse, and transplantation were considered potential alloimmunization sources. Results There were 1200 study patients (852 females; 348 males) at 30 institutions in 5 countries (USA, Canada, UK, New Zealand, Brazil). Most patients had a single potential source of alloimmunization identified (857/1200, 71%), most commonly pregnancy among females (537/852, 63%) and transfusion among males (180/348, 52%). When multiple potential sources were included, males were more likely than females to have a history of transfusion (235/348 [68%] vs. 149/852 [17%], p < .0001) and confirmed or suspected intravenous drug abuse (100/348 [29%] vs. 138/852 [16%], p < .0001). Among females with a history of pregnancy, 119/718 (17%) had healthcare access issues, 120/718 (17%) had pregnancy in a country where they may not have received RhIg, and 21/718 (3%) refused RhIg. Among patients with a history of transfusion, males were more likely than females to have received RhD‐positive red blood cells or whole blood (143/235 [61%] vs. 30/149 [20%], p < .0001) and/or platelets (84/235 [36%] vs. 19/149 [13%], p < .0001). Discussion Pregnancy was the most frequently identified potential source of RhD alloimmunization among females. Transfusion was most frequent in males. Intravenous drug abuse as a common potential source among patients with RhD alloimmunization merits further study.
Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease
Goyal, Gaurav , Bossert, Dana, Sigler, Allison , Rotemberg, Veronica , Francis, Jasmine H. , Rampal, Raajit K. , Diamond, Eli L. , Reiner, Anne S , Francis, Jasmine H , Diamond, Eli L , Goyal, Guarav , Reiner, Anne S. , Lacouture, Mario E. , Go, Ronald S.

Mayo Clinic

Blood | March 7, 2025 | Volume: 145 | Issue: 18 | Pages: 2100-2103

10.1182/blood.2024028032 | PMID 40053897 Get It

Abstract Among 64 patients with Erdheim-Chester disease treated with a BRAF inhibitor (median follow-up 4 years), we found high response rates (85%) but frequent discontinuations (61%), primarily because of adverse events. Additionally, patients experienced poor health-related quality of life and high symptom burden.